艾司洛尔对食管胃结合部的影响:14名健康志愿者的双盲随机交叉研究
该双盲随机交叉研究在14名健康志愿者中比较艾司洛尔与瑞芬太尼对食管胃结合部(EGJ)压力的影响,发现艾司洛尔不影响EGJ功能,而瑞芬太尼显著降低吸气与呼气EGJ压力,提示艾司洛尔在维持EGJ屏障功能方面可能具有优势。
要点
- 艾司洛尔不改变EGJ功能,可能有利于减少被动反流。
- 瑞芬太尼显著降低吸气和呼气EGJ压力。
- 在需维持EGJ屏障功能时,艾司洛尔或可替代瑞芬太尼。
核心结论
- 与瑞芬太尼相比,艾司洛尔不影响EGJ功能。
研究设计与样本
- 双盲随机交叉研究,纳入14名健康志愿者,使用高分辨率固态测压法测量EGJ压力。
临床怎么用
- 在需要维持EGJ屏障功能的麻醉场景中,艾司洛尔可能具有优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Passive regurgitation may occur throughout the perioperative period, increasing the risk for pulmonary aspiration and postoperative pulmonary complications. Hypnotics and opioids, especially remifentanil, that are used during anesthesia have been shown to decrease the pressure in the esophagogastric junction (EGJ), that otherwise acts as a barrier against passive regurgitation of gastric contents. Esmolol, usually used to counteract tachycardia and hypertension, has been shown to possess properties useful during general anesthesia. Like remifentanil, the β-1-adrenoreceptor antagonist may be used to attenuate the stress reaction to tracheal intubation and to modify perioperative anesthetic requirements. It may also reduce the need for opioids in the postoperative period. Its action on the EGJ is however unknown.The aim of this trial was to compare the effects of esmolol and remifentanil on EGJ pressures in healthy volunteers, when administrated as single drugs. METHODS: Measurements of EGJ pressures were made in 14 healthy volunteers using high-resolution solid-state manometry. Interventions were administered in a randomized sequence and consisted of esmolol that was given IV as a bolus dose of 1 mg/kg followed by an infusion of 10 μg·kg·minute over 15 minutes, and remifentanil with target-controlled infusion of 4 ng/mL over 15 minutes. Interventions were separated by a 20-minute washout period. Analyses of EGJ pressures were performed at baseline, and during drug administration at 2 (T2) and 15 minutes (T15). The primary outcome was the inspiratory EGJ augmentation, while the inspiratory and expiratory EGJ pressures were secondary outcomes. RESULTS: There was no effect on inspiratory EGJ augmentation when comparing remifentanil and esmolol (mean difference -4.0 mm Hg [-9.7 to 1.7]; P= .15). In contrast, remifentanil significantly decreased both inspiratory and expiratory pressures compared to esmolol (-12.2 [-18.6 to -5.7]; P= .003 and -8.0 [-13.3 to -2.8]; P= .006). CONCLUSIONS: Esmolol, compared with remifentanil, does not affect EGJ function. This may be an advantage regarding passive regurgitation and esmolol may thus have a role to play in anesthesia where maintenance of EGJ barrier function is of outmost importance.
引用
- Ander F, Magnuson A, Berggren L, et al. Effects of Esmolol on the Esophagogastric Junction: A Double-Blind, Randomized, Crossover Study on 14 Healthy Volunteers. Anesth Analg. 2017. PMID: 28763358. doi:10.1213/ANE.0000000000002339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。